Dali Pharmaceutical Co Ltd
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection. The company's products include xingnaojing, shenmai, and astragalus injections, as well as citicoline injections. It also has patents, including invention patents and utility models. The company was founded in 1996 and is headquartered in Dali,… Read more
Dali Pharmaceutical Co Ltd (603963) - Total Assets
Latest total assets as of September 2024: CN¥450.20 Million CNY
Based on the latest financial reports, Dali Pharmaceutical Co Ltd (603963) holds total assets worth CN¥450.20 Million CNY as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dali Pharmaceutical Co Ltd - Total Assets Trend (2012–2023)
This chart illustrates how Dali Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Dali Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2023)
Dali Pharmaceutical Co Ltd's total assets of CN¥450.20 Million consist of 61.0% current assets and 39.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.0% |
| Accounts Receivable | CN¥1.69 Million | 0.4% |
| Inventory | CN¥63.84 Million | 13.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥34.95 Million | 7.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2023)
This chart illustrates how Dali Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dali Pharmaceutical Co Ltd's current assets represent 61.0% of total assets in 2023, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2023, down from 27.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 10.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 13.5% of total assets.
Dali Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Dali Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Dali Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Dali Pharmaceutical Co Ltd generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Dali Pharmaceutical Co Ltd is currently not profitable relative to its asset base.
Dali Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.53 | 4.45 | 4.20 |
| Quick Ratio | 2.81 | 3.67 | 3.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥195.97 Million | CN¥ 215.58 Million | CN¥ 297.15 Million |
Dali Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Dali Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -5.9% |
| Total Assets | CN¥473.83 Million |
| Market Capitalization | $10.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dali Pharmaceutical Co Ltd's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Dali Pharmaceutical Co Ltd's assets decreased by 5.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Dali Pharmaceutical Co Ltd (2012–2023)
The table below shows the annual total assets of Dali Pharmaceutical Co Ltd from 2012 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | CN¥473.83 Million | -5.89% |
| 2022-12-31 | CN¥503.49 Million | -8.25% |
| 2021-12-31 | CN¥548.75 Million | -5.18% |
| 2020-12-31 | CN¥578.71 Million | +3.10% |
| 2019-12-31 | CN¥561.33 Million | -5.58% |
| 2018-12-31 | CN¥594.51 Million | -2.98% |
| 2017-12-31 | CN¥612.76 Million | +110.24% |
| 2016-12-31 | CN¥291.45 Million | -17.10% |
| 2015-12-31 | CN¥351.57 Million | -1.98% |
| 2014-12-31 | CN¥358.68 Million | +2.01% |
| 2013-12-31 | CN¥351.62 Million | +17.76% |
| 2012-12-31 | CN¥298.58 Million | -- |